Gary B. Gordon

TriSalus Life Sciences, Inc.Ayala Pharmaceuticals, Inc.Old Ayala, Inc

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 1 buy · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€34k

▼ Sales (0 ops.)

—

Latest filing published 15 May 2026 for TriSalus Life Sciences, Inc.. Read the official filing

Filing timeline

BuySale

Gary B. Gordon

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

T+90 mean return

-32.6%

Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.

Signal history

No signal scores available.

Gary B. Gordon: trading record in brief

Filings by Gary B. Gordon span 3 companies, the busiest being TriSalus Life Sciences, Inc., Ayala Pharmaceuticals, Inc. and Old Ayala, Inc. Between 16 May 2022 and 14 May 2026, the trades on record add up to 4 filings.

On the market, this insider has only ever bought: 1 purchase, €34k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 2 share grants. Since January 2026: 1 purchase and no sales on the market.

The latest filing, published on 15 May 2026, reports a share grant in TriSalus Life Sciences, Inc. The last purchase on record was published on 23 February 2026, which is 240 days ago. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.